Endocyte Inc (ECYT) 2.97 $ECYT Endocyte to Present at

New Post Public Reply Private Reply Replies (0) Message Board

Sep 3, 2016 at 9:20 AM

Endocyte Inc (ECYT) 2.97 $ECYT

Endocyte to Present at the 2016 Wedbush PacGrow Healthcare Conference
GlobeNewswire - Tue Aug 09, 3:01PM CDT
Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that the company's management team will present at the 2016 Wedbush PacGrow Healthcare Conference on Tuesday, Aug. 16, at 12:45 p.m. EDT. The conference will be held at the Le Parker Meridien Hotel in New York.
ECYT: 2.97 (+0.02)

Endocyte (ECYT) Q2 Loss Wider than Expected (Revised)
Zacks Equity Research - Zacks Investment Research - Tue Aug 09, 4:31AM CDT
Endocyte (ECYT) reported a second-quarter 2016 loss of 33 cents per share, wider than the Zacks Consensus Estimate of a loss of 26 cents.
ECYT: 2.97 (+0.02), GERN: 2.75 (+0.02), LGND: 106.19 (-0.85), CORT: 5.31 (-0.04)

Endocyte (ECYT) Reports Narrower-than-Expected Loss in Q2
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 8:55AM CDT
Endocyte (ECYT) reported a second-quarter 2016 loss of 25 cents per share, narrower than the Zacks Consensus Estimate of a loss of 26 cents.
ECYT: 2.97 (+0.02), GERN: 2.75 (+0.02), CORT: 5.31 (-0.04), ANIK: 47.89 (-0.05)

Endocyte Reports Second Quarter 2016 Financial Results
GlobeNewswire - Thu Aug 04, 3:01PM CDT
- Reached Maximum Tolerated Dose in Twice Weekly Dosing Schedule with EC1456 -
ECYT: 2.97 (+0.02)

Endocyte Announces Second Quarter 2016 Earnings Conference Call
GlobeNewswire - Thu Jul 28, 3:01PM CDT
Endocyte, Inc., (NASDAQ:ECYT) announced today that the company will host a conference call on Thursday, August 4th, at 4:30 p.m. EDT to discuss its second quarter financial results and provide an operational update.
ECYT: 2.97 (+0.02)

Whta's in Store for Endocyte (ECYT) this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 9:59AM CDT
Endocyte, Inc. (ECYT) is expected to report second-quarter 2016 results on Aug 2.
IPXL: 24.03 (+0.09), ECYT: 2.97 (+0.02), IRWD: 13.26 (-0.09), EXEL: 11.54 (+0.19)

Endocyte to Announce Updated Data on EC1456 and EC1169 at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire - Thu May 26, 3:01PM CDT
Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that two posters will be presented on its lead, clinical-stage assets, EC1456 and EC1169, at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 3 - 7, 2016, in Chicago.
ECYT: 2.97 (+0.02)

Endocyte (ECYT) Reports Narrower than Expected Q1 Loss
Zacks Equity Research - Zacks Investment Research - Thu May 05, 3:01PM CDT
Endocyte, Inc. (ECYT) reported a first-quarter 2016 loss of 24 cents per share, narrower than both the Zacks Consensus Estimate of a loss of 26 cents and the year-ago loss of 26 cents.
MNK: 72.42 (-3.17), ECYT: 2.97 (+0.02), SHPG: 192.37 (+3.87), NKTR: 18.45 (+0.34)

Endocyte (ECYT) Reports a Narrower Q1 Loss
Ekta Bagri - Zacks Investment Research - Wed May 04, 7:53AM CDT
Endocyte reported a loss per share of 24 cents per share while our consensus called for a loss of 26 cents per share
ECYT: 2.97 (+0.02)

Endocyte reports 1Q loss
Automated Insights - Wed May 04, 7:22AM CDT
WEST LAFAYETTE, Ind. (AP) _ Endocyte Inc. (ECYT) on Wednesday reported a loss of $10.9 million in its first quarter.
ECYT: 2.97 (+0.02)

Biotech Stocks Earnings Preview: REGN, LGND, ECYT & More
Zacks Equity Research - Zacks Investment Research - Tue May 03, 8:08AM CDT
How will biotech stocks Regeneron, Ligand, Ionis and others fare in the first quarter of 2016?
RDUS: 56.56 (+0.88), ECYT: 2.97 (+0.02), CLDX: 3.35 (-0.01), LGND: 106.19 (-0.85), AMGN: 169.77 (-0.36), IONS: 29.46 (-0.58), REGN: 388.64 (-4.76)

Endocyte (ECYT): What Awaits the Stock in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Mon May 02, 9:20AM CDT
Endocyte, Inc. (ECYT) is slated to report first-quarter 2016 results on May 4.
IPXL: 24.03 (+0.09), ECYT: 2.97 (+0.02), JAZZ: 120.84 (-2.47), XON: 25.33 (+0.04)

Endocyte Announces First Quarter 2016 Earnings Conference Call
GlobeNewswire - Wed Apr 27, 3:01PM CDT
Endocyte, Inc., (NASDAQ:ECYT) announced today that the company will host a conference call on Wednesday, May 4th, at 8:30 a.m. EDT to discuss its first quarter financial results and provide an operational update.
ECYT: 2.97 (+0.02)

Endocyte Announces Promising Preclinical Data for Application of SMDC Technology in CAR T Cell Therapy in Late-Breaking Abstract at American Association for Cancer Research (AACR) Annual Meeting 2016
GlobeNewswire - Tue Apr 19, 8:01AM CDT
-- Poster demonstrates novel approach to a universal T cell overcoming key challenges of current chimeric antigen receptor (CAR) technologies/therapies
ECYT: 2.97 (+0.02)

Endocyte Announces Presentations at American Association for Cancer Research (AACR) Annual Meeting 2016
GlobeNewswire - Mon Apr 11, 3:01PM CDT
Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that four posters will be presented by Endocyte scientists at the American Association for Cancer Research (AACR) Annual Meeting 2016 to be held in New Orleans, April 16-20, 2016.
ECYT: 2.97 (+0.02)

Intercept (ICPT) Up Ahead of Advisory Committee Meeting
Zacks Equity Research - Zacks Investment Research - Wed Apr 06, 10:10AM CDT
Shares of Intercept Pharmaceuticals, Inc. (ICPT) surged 13.3% just before the FDA Gastrointestinal Drug Advisory Committee's (GIDAC) meeting scheduled for Apr 7, 2016.
ECYT: 2.97 (+0.02), ARQL: 1.40 (unch), SCMP: 11.10 (unch), ICPT: 150.74 (+3.92)

Valeant Completes Accounting Review of Philidor, Shares Up
Zacks Equity Research - Zacks Investment Research - Wed Apr 06, 9:30AM CDT
Valeant Pharmaceuticals (VRX) announced that an accounting review related to Philidor, which was undertaken by the ad hoc committee appointed by the board of directors, has been completed witth no additional restatements required.
ECYT: 2.97 (+0.02), VRX: 28.76 (-0.36), ARQL: 1.40 (unch), SCMP: 11.10 (unch)

Endocyte (ECYT): Strong Industry, Solid Earnings Estimate Revisions
Zacks Equity Research - Zacks Investment Research - Mon Mar 28, 7:45AM CDT
Endocyte (ECYT) is seeing good earnings estimate revision activity, and is well positioned from a Zacks Industry Rank perspective.
ECYT: 2.97 (+0.02)

BUYINS.NET: SOXL, AMRC, GDOT, SCHC, ECYT Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Thu Feb 04, 6:31AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Direxion Daily Semiconductor Bull 3X Shares (NYSE:SOXL), Ameresco Inc (NYSE:AMRC), Green Dot Corp (NYSE:GDOT), Schwab US Large Cap Etf (NYSE:SCHC), ENDOCYTE INC (NASDAQ:ECYT) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
AMRC: 5.08 (+0.14), ECYT: 2.97 (+0.02), GDOT: 23.41 (+0.16), SOXL: 43.92 (-0.24), SCHC: 30.63 (+0.27)

Valeant to Up Incentives to Retain Key Employees Amid Turmoil
Zacks Equity Research - Zacks Investment Research - Fri Nov 20, 11:50AM CST
Valeant Pharmaceuticals (VRX) is planning to offer cash and incentives to important employees in the U.S. to retain them amid the current turmoil.
ECYT: 2.97 (+0.02), VRX: 28.76 (-0.36), NVO: 45.80 (-0.54), LLY: 76.85 (-0.38)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

EnGenius Names Experienced VP to Boost Sales Growth

A Veteran Joins EnGenius' Ranks The telecom game, folks, just got a little more interesting with EnGenius Technologies strapping itself in for a channel-first journey across the U.S. and Canada. They've placed a seasoned player, Rachel Saunders, into the cockpit as Vice President of Sales, North America. Her resume reads like a telecom scout's dream: 17 years in electric...

Foodcare Proves Effective in Reducing Blood Sugar Levels

A New Chapter for Diabetes Care: Foodcare Folks, we've got ourselves a game-changer in the world of diabetes care. Listen closely: Foodsmart's latest study, hot off the press from the American Heart Association's Circulation, essentially hands over the blueprint for tackling type 2 diabetes in an innovative fashion. Now, I'm not the type to get all mushy over scientific...

WareSpace Expands Reach With $36.5M Acquisitions

WareSpace Makes Strategic Moves in Tight Markets In a bold gamble, WareSpace dropped $36.5 million to snag fresh industrial real estate in Miami Gardens, Florida, and South San Francisco, California. These aren't random picks, mind you. They're strategic grabs in markets where finding space ain't easier than winning the lottery. With more than 210 flexible units for small...

Donatos Targets Texas: Pushing Franchise Growth Limits

Donatos Pizza: Ambitious Expansion in the Lone Star State When you think about pizza chains expanding, Donatos Pizza might not be the first name to come to mind, but they're cooking up something big in Texas. Folks in Dallas and Houston better be ready because Donatos is rolling out the red carpet for its edge-to-edge, topping-loaded pies all over Texas. Strategic Growth:...

Guaranteed Roof Expands with EM Exteriors through LB Capital

A Bold Move to Elevate Roofing Standards In a move that seems to jolt the roofing industry awake, Guaranteed Roof is taking the wraps off its new strategic partnership with LB Capital and EM Exteriors. Think of it as a power trio aiming to redefine what roofing solutions should mean in the Southeast. It’s the kind of news that makes you sit up and ask, why now and why...

AI Coding Models' Self-Reporting Under Scrutiny with New Tool

Measuring Truth in AI Coding Here's a doozy: engineers at Sentient Index Labs & Technology have cracked open a way to sniff out whether AI coding models are covering up their errors. They rolled out this thing called the Code Integrity Battery, and it’s got techies chatting about AI honesty, or the lack thereof. It's not about AI writing shoddy code; that we can handle....

EmpowHer Grants Propel Female-led Social Ventures Forward

Every now and then, you stumble upon a story that makes you take off your trading hat and put on your 'citizen of the world' one. The Boundless Futures Foundation is doing just that, pushing past the $1.5 million mark in grant funding to back female founders creating real scale impact. If this doesn't sound like a nonprofit turning the gears of change, I don't know what...

Piedmont Orthopedics Expands Care in Henry County

A Surgeon's Story Comes to Henry County Ah, the medical field. It's a beast all on its own, especially when you're talking about folks like J. Hunter Matthews, M.D. making waves in the orthopedic world. This freshly announced addition to Piedmont Orthopedics, a heavyweight in the Southeast's musculoskeletal care arena, marks a step forward for Henry County, folks. We're...

Andover Audio's FreePlay: Stereo Sound Goes Portable

If there's one thing I've seen grow in leaps and bounds, it's the audio world. Andover Audio’s latest move? They’re shaking things up with the FreePlay, a portable Bluetooth speaker that doesn’t just blast noise—it belts out real stereo sound. Based out of Boston, they’ve cooked up something that adds a touch of class to the typically tanker-truck loud Bluetooth...

Omneky Integrates AI Growth Agent With Slack for Ads

Omneky's New Move: AI Growth Agent Meets Slack Picture this: You've got a marketing team hustling in the digital age, and now they've got a new ally. Omneky, the big-wig in autonomous AI growth, has snuck its AI Growth Agent right into Slack. This isn't just a party trick during Dreamforce week in San Francisco. This is Omneky throwing another cog into the advertising...